Stock Comparison

CRSP vs KRYS

CRISPR Therapeutics AG vs Krystal Biotech Inc

The Verdict

KRYS takes this one.

CRSP

CRISPR Therapeutics AG

8.6

out of 10

Hidden Gem

Winner

KRYS

Krystal Biotech Inc

9.0

out of 10

Hidden Gem

Head-to-Head

$4.4B

Market Cap

N/A

-7.1

P/E Ratio

N/A

0.0%

Profit Margin

N/A

-26.3%

Return on Equity

N/A

0.1

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

8.6

DVR Score

9.0

The Deep Dive

CRSP8.6/10

CRISPR Therapeutics remains a high-potential player in gene editing, positioned for transformative growth. The successful commercialization of Casgevy (with Vertex) and planned pediatric filings in H1 2026 solidify its market entry and de-risk early revenue generation, albeit with a reported ~97.8% YoY revenue decline in an unspecified recent period, indicating challenges in early commercial ramp-...

Full CRSP Analysis

KRYS9.0/10

Krystal Biotech maintains its strong '10x potential' trajectory. Vyjuvek's continued robust commercial performance for DEB provides a solid financial base, validating execution. The proprietary STAR-D platform, particularly the AATD program, shows accelerated progress with pivotal clinical readouts anticipated to significantly expand the Total Addressable Market. The leadership's proven ability to...

Full KRYS Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.